Avapritinib Earns FDA Approval For Advanced Systemic Mastocytosis, Including Mast Cell Leukemia
Avapritinib is now fully approved to treated advanced systemic mastocytosis, according to phase 1 and phase 2 clinical trial data.
Related Articles
PM8002/BNT327 Combo Improves Efficacy and Safety in Metastatic TNBC
Data from a phase 1b/2 study show a 78.6% ORR in patients with metastatic triple-negative breast cancer treated with PM8002/BNT327 plus nab-paclitaxel.
Osimertinib With or Without Chemo is Top Choice for Frontline NSCLC
The NCCN guidelines have stated that osimertinib is the preferred category 1 treatment for patients with EGFR-mutated NSCLC discovered before the first line of therapy.
Reducing Post-Mastectomy Disparities in Breast Cancer Minority Populations
A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.
DARA + VRd in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Analysis of Minimal Residual Disease in the PERSEUS Trial
Hematologic oncology specialists review recent data from the PERSEUS trial analyzing minimal residual disease in patients with newly diagnosed multiple myeloma who receive DARA-VRd.
Prior CAR T-Cell Therapy Exposure May Impact Odronextamab Benefit in DLBCL
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Obe-cel Elicits Durable Responses in Relapsed/Refractory B-Cell ALL
In the phase 1b/2 FELIX study, obecabtagene autoleucel was associated with low incidence of grade 3 or higher immune-related toxicity.
CAR T-Cell Therapy in Multiple Myeloma: Clinical Data and Patient Selection
A panel of experts on multiple myeloma discuss the role of CAR T-cell therapy in the evolving treatment landscape, highlighting clinical trial data, recent approvals,…
Top 10 Findings Shaping the Future of Breast Cancer Care From SABCS 2024
SABCS 2024 saw a variety of potentially practice-changing findings on novel antibody drug conjugates, biomarker data, and surgical interventions.
Treatment Sequencing Strategies in R/R Multiple Myeloma
A panel of experts on multiple myeloma review patient cases and discuss the treatment of patients with relapsed/refractory disease, highlighting sequencing strategies and clinical trials…
Assessing Cosibelimab’s Future in Cutaneous Squamous Cell Carcinoma
According to Jason Luke, MD, FACP, there is still room to improve response rates in CSCC treatment, but there is excitement surrounding future of treatment…